LAVA Therapeutics N.V.
NASDAQ:LVTX
Overview | Financials
Company Name | LAVA Therapeutics N.V. |
Symbol | LVTX |
Currency | USD |
Price | 0.975 |
Market Cap | 25,640,153 |
Dividend Yield | 0% |
52-week-range | 0.96 - 6.47 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stephen Allen Hurly M.B.A., M.Sc. |
Website | https://www.lavatherapeutics.com |
An error occurred while fetching data.
About LAVA Therapeutics N.V.
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD